A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
NCT ID: NCT03845517 Phase: PHASE2 Status: COMPLETED Enrollment: 350 Completion: 2023-10-05
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
Summary
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
Primary Outcome
Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52